La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Novo Nordisk Croissance future

Future contrôle des critères 3/6

Novo Nordisk devrait augmenter ses bénéfices et son chiffre d'affaires de 14.4% et de 13.3% par an respectivement. Le BPA devrait croître de de 15.3% par an. Le rendement des capitaux propres devrait être 65% dans 3 ans.

Informations clés

14.4%

Taux de croissance des bénéfices

15.3%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	23.6%
Taux de croissance des recettes	13.2%
Rendement futur des capitaux propres	65.2%
Couverture par les analystes	Good
Dernière mise à jour	30 Sep 2024

Mises à jour récentes de la croissance future

Recent updates

Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy

Sep 18

Novo Nordisk: Low Dividend Yield, Decelerated Growth Rates, Hold For Now

Sep 10

Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation

Aug 18

Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy

Feb 23

Novo Nordisk: Irrational Exuberance Isn't Worth The Risk

Feb 16

Novo Nordisk: Outlook For Weight Loss Drugs In 2024

Jan 22

Taking Novo Nordisk To The Next Level

Jan 15

Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly

Jan 02

Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity

Dec 12

Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation

Nov 24

Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion

Oct 24

Novo Nordisk: Catching The Falling Knife Now Could Really Hurt

Sep 22

Novo Nordisk: Strong Fundamentals Meet Technical Uptrends

Aug 30

Novo Nordisk: Denmark's Coca-Cola

Jul 25

The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier

Jul 11

Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care

Jun 23

Prévisions de croissance des bénéfices et des revenus

NYSE:NVO - Estimations futures des analystes et données financières antérieures (DKK Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	403,393	148,812	117,856	163,100	21
12/31/2025	347,490	127,583	93,716	140,188	25
12/31/2024	289,289	101,589	70,649	123,714	25
6/30/2024	258,003	89,898	66,027	115,334	N/A
3/31/2024	244,243	89,276	50,304	93,408	N/A
12/31/2023	232,261	83,683	70,012	108,908	N/A
9/30/2023	214,490	75,312	77,825	106,458	N/A
6/30/2023	201,325	67,239	67,497	89,731	N/A
3/31/2023	188,290	61,129	67,341	85,115	N/A
12/31/2022	176,954	55,525	64,134	78,887	N/A
9/30/2022	167,195	52,825	57,875	68,769	N/A
6/30/2022	157,251	50,539	57,680	66,037	N/A
3/31/2022	149,027	49,344	59,665	67,331	N/A
12/31/2021	140,800	47,757	47,615	55,000	N/A
9/30/2021	134,605	46,183	40,213	58,189	N/A
6/30/2021	129,910	44,362	31,814	54,188	N/A
3/31/2021	126,875	42,864	31,337	53,194	N/A
12/31/2020	126,946	42,138	29,870	51,951	N/A
9/30/2020	127,225	41,537	44,800	56,944	N/A
6/30/2020	126,575	41,433	47,621	56,126	N/A
3/31/2020	126,605	40,403	36,987	46,904	N/A
12/31/2019	122,021	38,951	35,551	46,782	N/A
9/30/2019	119,336	38,731	36,785	49,029	N/A
6/30/2019	116,821	37,574	31,251	43,960	N/A
3/31/2019	114,192	38,322	32,202	44,691	N/A
12/31/2018	111,831	38,628	32,206	44,616	N/A
9/30/2018	110,091	38,384	31,576	43,236	N/A
6/30/2018	108,943	39,117	33,787	44,538	N/A
3/31/2018	110,174	38,725	N/A	38,885	N/A
12/31/2017	111,696	38,130	N/A	41,168	N/A
9/30/2017	113,276	38,576	N/A	46,289	N/A
6/30/2017	114,199	38,609	N/A	48,557	N/A
3/31/2017	113,020	38,626	N/A	52,937	N/A
12/31/2016	111,780	37,925	N/A	48,314	N/A
9/30/2016	111,084	37,484	N/A	47,280	N/A
6/30/2016	110,339	36,064	N/A	44,179	N/A
3/31/2016	109,939	34,439	N/A	41,656	N/A
12/31/2015	107,927	34,860	N/A	38,287	N/A
9/30/2015	103,636	33,131	N/A	35,469	N/A
6/30/2015	99,093	31,248	N/A	35,578	N/A
3/31/2015	93,663	29,899	N/A	31,729	N/A
12/31/2014	88,806	26,481	N/A	31,692	N/A
9/30/2014	85,919	26,005	N/A	29,763	N/A
6/30/2014	84,181	25,920	N/A	23,783	N/A
3/31/2014	83,932	25,660	N/A	22,941	N/A
12/31/2013	83,572	25,184	N/A	25,942	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de NVO ( 14.4% par an) est supérieure au taux d'épargne ( 2.5% ).

Bénéfices vs marché: Les bénéfices de NVO ( 14.4% par an) devraient croître plus lentement que le marché US ( 15.2% par an).

Croissance élevée des bénéfices: Les bénéfices de NVO devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de NVO ( 13.3% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de NVO ( 13.3% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de NVO devrait être très élevé dans 3 ans ( 65 %).

Novo Nordisk Croissance future

Future contrôle des critères 3/6

Informations clés

Mises à jour récentes de la croissance future

Novo Nordisk A/S Provides Earnings Guidance for the Year 2024

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Recent updates

Novo Nordisk A/S Announces Monlunabant Phase 2A Trial in Obesity Successfully Completed

Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy

Aragen Life Sciences Reportedly Plans to Dilute About 10% Stake

Novo Nordisk: Low Dividend Yield, Decelerated Growth Rates, Hold For Now

Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation

Novo Nordisk A/S Decides to Pay Interim Dividend for 2024, Payable on 19 August 2024 for A and B Shares and 26 August 2024 for ADRs

Novo Nordisk: Growth Only Limited By Manufacturing Capacity

Novo Nordisk A/S Provides Earnings Guidance for the Year 2024

Novo Nordisk: Better Buying Opportunities Ahead

European Regulatory Authority Adopts A Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events

Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec

Novo Nordisk: Buy On Dips

Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy

Novo Nordisk: Leading The Fight Against Diabetes And Obesity

Novo Nordisk: Considerable Growth Beyond Ozempic

The FTC Cracks Down On Novo Nordisk's Ozempic

Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada

Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy

Novo Nordisk: The Moat Won't Last Forever

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified

Novo Nordisk, A Very Healthy Pharma Stalwart

Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy

Novo Nordisk: Irrational Exuberance Isn't Worth The Risk

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.